Deciphera Pharmaceuticals (NASDAQ:DCPH) Shares Down 3.6%

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report)'s stock price traded down 3.6% on Monday . The stock traded as low as $14.78 and last traded at $14.79. 55,852 shares changed hands during trading, a decline of 89% from the average session volume of 530,911 shares. The stock had previously closed at $15.34.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Wednesday, March 20th. Stifel Nicolaus boosted their target price on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $23.00.

Deciphera Pharmaceuticals Price Performance

The stock's fifty day moving average is $15.60 and its 200-day moving average is $14.09. The stock has a market capitalization of $1.21 billion, a PE ratio of -6.55 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The firm had revenue of $48.30 million for the quarter, compared to the consensus estimate of $45.93 million. During the same period in the prior year, the firm posted ($0.60) earnings per share. The firm's quarterly revenue was up 32.9% compared to the same quarter last year. On average, analysts forecast that Deciphera Pharmaceuticals, Inc. will post -2.16 EPS for the current year.

Insiders Place Their Bets

In other Deciphera Pharmaceuticals news, EVP Matthew L. Sherman sold 2,435 shares of the company's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $14.47, for a total transaction of $35,234.45. Following the completion of the transaction, the executive vice president now directly owns 94,079 shares in the company, valued at $1,361,323.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.43% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. raised its position in shares of Deciphera Pharmaceuticals by 96.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company's stock valued at $26,000 after buying an additional 997 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at about $30,000. Lazard Asset Management LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the first quarter valued at about $57,000. Compass Wealth Management LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at about $70,000. Finally, Advisor Group Holdings Inc. raised its position in shares of Deciphera Pharmaceuticals by 78.0% in the fourth quarter. Advisor Group Holdings Inc. now owns 4,331 shares of the company's stock valued at $71,000 after buying an additional 1,898 shares during the last quarter. 70.96% of the stock is currently owned by institutional investors and hedge funds.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.